POPCaP Act of 2026
- Sponsor
- Sen. Moran, Jerry [R-KS]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Jul 15, 2026
Bottom line
The bill establishes a nationwide precision oncology program for prostate cancer within the VA, aiming to provide advanced, personalized treatment and research opportunities for veterans.
What it actually does
This bill directs the Secretary of Veterans Affairs to establish a comprehensive precision oncology program for prostate cancer within the Department of Veterans Affairs. It designates 32 provisional medical facilities as centers of excellence, mandates specific activities and staffing for these centers, creates a Program Leadership team, and requires annual reporting to Congress on program performance and outcomes. It also authorizes specific appropriations for the program's initial years.
Proponents argue
Supporters argue that this program will significantly enhance the quality of care for veterans diagnosed with prostate cancer by providing access to cutting-edge precision medicine, including genetic sequencing and biomarker-specific clinical trials. They contend it will improve survival rates and ensure that veterans receive personalized treatment plans based on the latest research, leveraging a coordinated network of specialized VA centers.
Opponents contend
Potential opponents might raise concerns about the substantial financial commitment required to establish and maintain 32 specialized centers, including the costs of staffing, equipment, and research. They may also question the administrative feasibility of coordinating such a large network and whether these resources could be more effectively utilized for broader cancer care initiatives or other pressing veteran health priorities.
The bill is concise and well-structured, allowing for a thorough understanding of its provisions within a reasonable timeframe.
Section 2(a), adding 38 U.S.C. 7330E(a)-(b)
Establishment of Precision Oncology Program for Prostate Cancer (POPCaP)
This provision directs the Secretary of Veterans Affairs to establish the Precision Oncology Program for Cancer of the Prostate (POPCaP) within the Department. It specifies that any veteran diagnosed with prostate cancer is eligible to participate in this new program, ensuring a broad reach for specialized care.
Supporters argue
Proponents argue this establishes a vital program to address a prevalent and serious health issue among veterans, ensuring they receive the most advanced and personalized care available for prostate cancer.
Critics contend
No specific opposition is typically raised against the establishment of programs to improve veteran healthcare, though concerns about funding and resource allocation may arise.
Tradeoffs
The primary tension is balancing the need for specialized care with the overall resource allocation within the VA healthcare system.
Section 2(a), adding 38 U.S.C. 7330E(c)(1)
Designation of Provisional Centers of Excellence
This section mandates the immediate designation of 32 specific VA medical facilities across the country as provisional centers of excellence for the POPCaP program. These centers are listed by name and location, forming the initial network for delivering precision oncology services.
Section 2(a), adding 38 U.S.C. 7330E(c)(2), (4), (5)
Operational Requirements, Performance Reviews, and Termination of Centers
This provision sets operational standards for the centers, requiring at least 21 centers to be active at all times, with at least one in each Veterans Integrated Service Network (VISN). It also establishes a process for performance reviews starting in 2030 on a rolling cycle, and allows the Secretary to terminate a center's designation after January 1, 2030, if it fails to meet program purposes, following a 60-day notice to Congress.
Section 2(a), adding 38 U.S.C. 7330E(d)(1)
Mandated Activities for Centers of Excellence
Each designated center must carry out specific activities, including establishing genetic sequencing for advanced prostate cancer, instituting a uniform sequencing platform, participating in a telemedicine tumor board and a registry study, providing travel support for veterans with mutations, developing biomarker-specific clinical trials, and participating in industry-sponsored studies. Centers must also report progress to the Program Leadership team and extend resources to affiliated VISN centers.
Section 2(a), adding 38 U.S.C. 7330E(d)(2)
Minimum Staffing Requirements for Centers
This provision mandates that each designated center of excellence must employ a minimum set of specialized staff. This includes a medical oncologist, an interventional radiologist, a urologist, a radiation oncologist, a pathologist, and two full-time equivalent research staff members, ensuring a multidisciplinary approach to care and research.
Section 2(a), adding 38 U.S.C. 7330E(e)
Establishment and Duties of Program Leadership Team
The bill establishes a Program Leadership team, to be located at the Seattle VA Medical Center, comprising an Executive Director, Clinical Director, and Research Director. This team is responsible for strategic liaison with industry, coordinating participation in National Cancer Institute studies, facilitating study development, creating a model for hybrid decentralized clinical trials, maintaining a prostate cancer registry, and fostering expertise across the Department.
Section 2(a), adding 38 U.S.C. 7330E(f)
Annual Reporting Requirements to Congress
This provision mandates that the Secretary of Veterans Affairs submit an annual report to Congress by March 1st each year. The report must detail funding levels, the number of veterans served, participating investigators, publications, clinical research studies, veteran enrollment in studies, five-year survival rates compared to other populations, and outcomes data. A comprehensive plan for center operations is due in 2029, and performance review findings must be included starting in 2031.
Section 2(d)
Authorization of Appropriations
This section authorizes the appropriation of $15,500,000 for the Secretary of Veterans Affairs for each of fiscal years 2027, 2028, and 2029. These funds are specifically designated to carry out the Precision Oncology Program for Cancer of the Prostate, providing initial financial backing for its establishment and operation.
The designation and operation of the centers of excellence shall be conducted under the same terms and conditions and in the same manner as those centers were designated and operated on January 1, 2023.
Section 2(b)(2)
Why it matters:This phrasing is likely standard legislative practice to leverage existing, perhaps informal or pilot, operations and formalize them, rather than starting entirely from scratch. It implies a continuity of practice.
Case for: Supporters would argue this ensures a smooth transition and builds upon existing successful models or infrastructure within the VA, preventing unnecessary disruption and accelerating implementation by formalizing proven methods.
Case against: Critics might argue that referencing external, undefined 'terms and conditions' from a past date reduces transparency and limits congressional oversight, as the specific operational details are not explicitly codified within the bill itself.
Estimated impact: This clause significantly shapes the operational framework of the entire program by anchoring its implementation to a pre-existing, though unspecified, set of practices and conditions.